Zevra Therapeutics, Inc. · NASDAQ:ZVRA
Zevra Therapeutics — Q1 2023 Earnings Presentation
15 slides from Zevra Therapeutics's earnings presentation, May 15, 2023
Slide 1: Q1 2023 Results
Q1 2023 Results May 15, 2023 SZEVRA THERAPEUTICS Trademarks herein are held by their respective owners.
Slide 2: Cautionary Note Regarding Presentation Information
| 2 Z Cautionary Note Regarding Presentation SAZEV Information This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current fac
Slide 3: Agenda
Agenda SZEVRA THERAPEUTICS First Quarter 2023 Overview + Tamara Favorito, Zevra Board Chair Highlights and Program Updates + Christal Mickle, Chief Development Officer, Co-Founder, and Interim CEO and President effective June 1, 2023 AZSTARYS® Commercial Update, First Quarter 2023 Financial Results
Slide 4: Changes to Leadership Team and Board
2\A\A SAN Changes to Leadership Team and Board THERAPEUTICS Advancing the rare disease pipeline remains the top priority « Announced Board and Chief Executive Officer (CEO) changes: « John B. Bode, Douglas W. Calder, Wendy Dixon and Corey Watton joined the Board of Directors at the 2023 Annual Meeti
Slide 5: 1Q 2023 Highlights
VA SSSANY 1Q 2023 Highlights SZEVRA THERAPEUTICS + NDA resubmission as early as Q3 2023 + Completion of 4-year safety trial + Data presentation at WorldSymposium 2023 + Phase 2 trial ongoing in idiopathic hypersomnia + IND opened for narcolepsy + Net revenue of $2.9M for Q1 2023 * Cash, cash equival
Slide 6: Arimoclomol — Innovative Product Addresses High Unmet Need in NPC
Arimoclomol — Innovative Product Addresses High Unmet Need in NPC oA FIRST-IN-CLASS, ORAL TREATMENT » Capsule can be swallowed whole, opened and mixed with foods/liquids or delivered through feeding tube « Significant improvements in lysosomal and cellular function with arimoclomol treatment @) EXTE
Slide 7: Near-Term Opportunity to Commercialize and Retain Full Market Value
4.1. _Saa\\ Near-Term Opportunity to Commercialize SZEV and Retain Full Market Value Launch arimoclomol with « Small, nimble commercial team a small, focused « Lower marketing spend commercialization effort ¢ Patient advocacy relationships support which can be foundation adoption for future rare dis
Slide 8: KP1077 — Novel Approach to Rare Sleep Disorders
VAAN KP1077 — Novel Approach to Rare Sleep oA SERDEXMETHYLPHENIDATE FOR RARE SLEEP DISORDERS » Two dosing regimens being explored * Once daily at night * 2x daily-once in the morning and once at night Potential to address primary IH symptoms: sleep inertia and brain fog @) KO, IMPROVED SAFETY & TOLE
Slide 9: KP1077 — Multiple Clinical Programs Targeting Rare Sleep Indications
KP1077 — Multiple Clinical Programs “ZEVRA Targeting Rare Sleep Indications KP1077 Represents a Potential “Portfolio in a Pill” Opportunity » Lead KP1077 indication » IND opened for narcolepsy * Ongoing Phase 2 clinical trial was initiated in » Second KP1077 indication allows Zevra to December 2022
Slide 10: AZSTARYS Prescription Trends Are Encouraging
ACA 1 SSSANN AZSTARYS® Prescription Trends Are SZEVRA Encouraging Potential to achieve one or more net sales milestones based on current trend AZSTARYS TRx Since Launch’ Week ending mm ‘Drs Te 9,000 8,000 7,000 Meaningful change in trend one line beginning Q3 2022 oe TRx Count 8 4,000 ‘Week ending J
Slide 11: AZSTARYS Commercial Product Delivering Value
ACA SSSSSANN AZSTARYS® Commercial Product Delivering Value Y APPROVED BY THE U.S. FDA IN MARCH 2021 INDICATED FOR TREATMENT OF ADHD IN PATIENTS 6 YEARS OF AGE AND OLDER 2&= COMMERCIAL LICENSE TO CORIUM, INC. Corium has achieved coverage with three largest PBMs Field sales force to 175 reps, supporte
Slide 12: Financial Position is a Source of Strength
Financial Position is a Source of Strength THERAPEUTICS Q1 2023 Financial Results: + Net Revenue: * Q1 2023 was $2.9M; derived primarily from French EAP reimbursements of $2.3 and AZSTARYS royalties of $0.6M + Net Loss Attributable to Common Stockholders: * Q1 2023 was ($11.8M), or ($0.34) per basic
Slide 13: 2023 Financial Guidance
2023 Financial Guidance THERAPEUTICS Cash balance remains strong, with potential to realize milestone revenue Available cash, cash equivalents and investments expected to extend cash runway into 2026 * Current operating plan includes the expected reimbursements from the French arimoclomol EAP, the f
Slide 14: Significant Value Creation through Continued Execution
Significant Value Creation through Continued Execution Advancing Pipeline Realizing Commercial Opportunity & Retaining Value + Launch arimoclomol with small, focused commercialization effort + In-house commercial team provides foundation for future rare disease product commercialization * Clinical,
Slide 15: U. — [a4 > Lu N n oO (fo =) Ww a < a
U. — [a4 > Lu N n oO (fo =) Ww a < a Ww = (S k Yo AY an Th